Finasteride on Prostate and angiogenesis.docVIP

 PAGE \* MERGEFORMAT 11 Finasteride on Prostate and angiogenesis Study: Chun-ling Cao Huifeng Niu Wenbin Wei Wei [Keywords:] prostate cancer, angiogenesis, hypoxia inducible factor 1 @, vascular endothelial growth factor 5 @ reductase inhibitor finasteride is widely used in the treatment of benign prostatic hyperplasia (BPH, inhibits angiogenesis of prostate hyperplasia. Preliminary observations suggest that finasteride reduces dihydrotestosterone (DHT and prostate-specific antigen (PSA) level, the control of prostate growth and prostate cancer (PCa) play an important role in the occurrence and development (1,2), but its mechanism remains unclear. The retrospective study of patients in our hospital 429 cases of BPH drug treatment history, PCa incidence Gleason score and pathological conditions, evaluation of finasteride on the incidence of PCa and the impact of histological grade, and to explore finasteride on PCa angiogenesis. 1 Subjects and methods 1.1 Object Collected from 2004 to 2008 in our hospital were diagnosed 429 cases of BPH, aged 68 to 87 (mean (77.6 + -7.8) years, finishing his history of BPH drugs. According to the treatment of BPH drugs in different patients, subjects were divided into finasteride group (n = 214 and the control group (n = 215. finasteride group of patients continuing medication at all times in the 6 to 14 months of finasteride in the two groups were 20 patients in the control group of 32 patients (52 patients) by B ultrasound-guided puncture biopsy or resection of the prostate diagnosed as PCa. 1.2 Methods 1.2.1 PCa finasteride on the incidence and the impact of histological grade All confirmed cases in two groups of pathological data for the analysis of PCa, graded according to Gleason grading system: well-differentiated adenocarcinoma (Gleason 2 ~ 6 points), moderately differentiated adenocarcinoma (Gleason 7 points), poorly differentiated adenocarcinoma (Gleasons 8 ~ 10 points). Analysis of the incid